Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

Advanced Drug Delivery Reviews

Volumn 58, Issue 8, 2006, Pages 916-930

  van der Burg, Sjoerd H ^a   Bijker, Martijn S ^a   Welters, Marij J P ^a   Offringa, R ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvants; Cell mediated immunity; Immunotherapy; Peptides; Tumour antigens

Indexed keywords

AMINO ACIDS; BIOMEDICAL ENGINEERING; CONTROLLED DRUG DELIVERY; IMMUNOLOGY; PROTEINS;

ADJUVANTS; CELL-MEDIATED IMMUNITY; IMMUNOTHERAPY; TUMOR ANTIGENS;

VACCINES;

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE PEPTIDE VACCINE; EPITOPE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN PAPILLOMA VIRUS 16 E 6 VACCINE; HUMAN PAPILLOMA VIRUS 16 E 7 VACCINE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINIA VACCINE; WART VIRUS VACCINE; WT1 PROTEIN;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; HELPER CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION CONTROL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS VECTOR;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SYNTHETIC;

EID: 33750705600     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2005.11.003     Document Type: Review

References (117)

1. Schulz M., Zinkernagel R.M., and Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 991-993
2. Kast W.M., Roux L., Curren J., Blom H.J., Voordouw A.C., Meloen R.H., Kolakofsky D., and Melief C.J. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2283-2287
3. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., ter Schegget J., Melief C.J., and Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23 (1993) 2242-2249
4. Mandelboim O., Vadai E., Fridkin M., Katz-Hillel A., Feldman M., Berke G., and Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1 (1995) 1179-1183
5. Widmann C., Romero P., Maryanski J.L., Corradin G., and Valmori D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 155 (1992) 95-99
6. Kyburz D., Aichele P., Speiser D.E., Hengartner H., Zinkernagel R.M., and Pircher H. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23 (1993) 1956-1962
7. Toes R.E., Blom R.J., Offringa R., Kast W.M., and Melief C.J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156 (1996) 3911-3918
8. Toes R.E., Offringa R., Blom R.J., Melief C.J., and Kast W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7855-7860
9. Mocellin S., Mandruzzato S., Bronte V., Lise M., and Nitti D. Part I: vaccines for solid tumours. Lancet Oncol. 5 (2004) 681-689
10. van der Burg S.H., Visseren M.J., Brandt R.M., Kast W.M., and Melief C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156 (1996) 3308-3314
11. Dyall R., Bowne W.B., Weber L.W., LeMaoult J., Szabo P., Moroi Y., Piskun G., Lewis J.J., Houghton A.N., and Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188 (1998) 1553-1561
12. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., and White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
13. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S., Gee C., Lau R., Jeffery G., Margolin K., Marty V., and Weber J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19 (2001) 3836-3847
14. Weber J. Peptide vaccines for cancer. Cancer Investig. 20 (2002) 208-221
15. Smith II J.W., Walker E.B., Fox B.A., Haley D., Wisner K.P., Doran T., Fisher B., Justice L., Wood W., Vetto J., Maecker H., Dols A., Meijer S., Hu H.M., Romero P., Alvord W.G., and Urba W.J. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 21 (2003) 1562-1573
16. Lienard D., Rimoldi D., Marchand M., Dietrich P.Y., van Baren N., Geldhof C., Batard P., Guillaume P., Ayyoub M., Pittet M.J., Zippelius A., Fleischhauer K., Lejeune F., Cerottini J.C., Romero P., and Speiser D.E. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol. 4 (2004) 4
17. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O.A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihara S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., and Sugiyama H. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13885-13890
18. Fayolle C., Deriaud E., and Leclerc C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+T cell help. J. Immunol. 147 (1991) 4069-4073
19. Ossendorp F., Mengede E., Camps M., Filius R., and Melief C.J.M. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187 (1998) 1-10
20. Scheibenbogen C., Schadendorf D., Bechrakis N.E., Nagorsen D., Hofmann U., Servetopoulou F., Letsch A., Philipp A., Foerster M.H., Schmittel A., Thiel E., and Keilholz U. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer 104 (2003) 188-194
21. Shirai M., Pendleton C.D., Ahlers J., Takeshita T., Newman M., and Berzofsky J.A. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+CTL in vivo with peptide vaccine constructs. J. Immunol. 152 (1994) 549-556
22. Hiranuma K., Tamaki S., Nishimura Y., Kusuki S., Isogawa M., Kim G., Kaito M., Kuribayashi K., Adachi Y., and Yasutomi Y. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80 (1999) 187-193
23. Bennett S.R.M., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F.A.P., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 (1998) 478-480
24. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
25. Matloubian M., Concepcion R.J., and Ahmed R. CD4+T cells are required to sustain CD8+cytotoxic T-cell responses during chronic viral infection. J. Virol. 68 (1994) 8056-8063
26. Buhlmann J.E., Gonzalez M., Ginther B., Panoskaltsis-Mortari A., Blazar B.R., Greiner D.L., Rossini A.A., Flavell R., and Noelle R.J. Cutting edge: sustained expansion of CD8+T cells requires CD154 expression by Th cells in acute graft versus host disease. J. Immunol. 162 (1999) 4373-4376
27. Schuurhuis D.H., Laban S., Toes R.E., Ricciardi-Castagnoli P., Kleijmeer M.J., van der Voort E.I., Rea D., Offringa R., Geuze H.J., Melief C.J., and Ossendorp F. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or-dependent stimuli. J. Exp. Med. 192 (2000) 145-150
28. Slingluff Jr. C.L., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., Kittlesen D., Deacon D., Hibbitts S., Grosh W.W., Petroni G., Cohen R., Wiernasz C., Patterson J.W., Conway B.P., and Ross W.G. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7 (2001) 3012-3024
29. Kloetzel P.M., and Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16 (2004) 76-81
30. Melief C.J. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur. J. Immunol. 33 (2003) 2645-2654
31. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., van der Burg S.H., and Melief C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169 (2002) 350-358
32. Zeng G., Li Y., El-Gamil M., Sidney J., Sette A., Wang R.F., Rosenberg S.A., and Robbins P.F. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62 (2002) 3630-3635
33. Knutson K.L., Schiffman K., and Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107 (2001) 477-484
34. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54 (2005) 721-728
35. Lopez J.A., Weilenman C., Audran R., Roggero M.A., Bonelo A., Tiercy J.M., Spertini F., and Corradin G. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol. 31 (2001) 1989-1998
36. Bennett S.R., Carbone F.R., Toy T., Miller J.F., and Heath W.R. B cells directly tolerize CD8(+) T cells. J. Exp. Med. 188 (1998) 1977-1983
37. Toes R.E., van der Voort E.I., Schoenberger S.P., Drijfhout J.W., van Bloois L., Storm G., Kast W.M., Offringa R., and Melief C.J. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160 (1998) 4449-4456
38. Lefrancois L., Marzo A., and Williams K. Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo. J. Immunol. 171 (2003) 2832-2839
39. Falo Jr. L.D., Colarusso L.J., Benacerraf B., and Rock K.L. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 8347-8350
40. Amoscato A.A., Prenovitz D.A., and Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161 (1998) 4023-4032
41. Larsen S.L., Pedersen L.O., Buus S., and Stryhn A. T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med. 184 (1996) 183-189
42. Blanchet J.S., Valmori D., Dufau I., Ayyoub M., Nguyen C., Guillaume P., Monsarrat B., Cerottini J.C., Romero P., and Gairin J.E. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 167 (2001) 5852-5861
43. Garcia K.C., Teyton L., and Wilson I.A. Structural basis of T cell recognition. Annu. Rev. Immunol. 17 (1999) 369-397
44. Powell Jr. D.J., and Rosenberg S.A. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27 (2004) 36-47
45. Dutoit V., Taub R.N., Papadopoulos K.P., Talbot S., Keohan M.L., Brehm M., Gnjatic S., Harris P.E., Bisikirska B., Guillaume P., Cerottini J.C., Hesdorffer C.S., Old L.J., and Valmori D. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 110 (2002) 1813-1822
46. *04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27 (2004) 472-477
47. Anderton S.M., Viner N.J., Matharu P., Lowrey P.A., and Wraith D.C. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat. Immunol. 3 (2002) 175-181
48. Offringa R., van der Burg S.H., Ossendorp F., Toes R.E., and Melief C.J. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12 (2000) 576-582
49. Ou D., Chong P., Tingle A.J., and Gillam S. Mapping T-cell epitopes of rubella virus structural proteins E1, E2, and C recognized by T-cell lines and clones derived from infected and immunized populations. J. Med. Virol. 40 (1993) 175-183
50. McCarthy M., Lovett A., Kerman R.H., Overstreet A., and Wolinsky J.S. Immunodominant T-cell epitopes of rubella virus structural proteins defined by synthetic peptides. J. Virol. 67 (1993) 673-681
51. van der Burg S.H., Klein M.R., Pontesilli O., Holwerda A.M., Drijfhout J.W., Kast W.M., Miedema F., and Melief C.J. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. J. Immunol. 159 (1997) 3648-3654
52. *0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191 (2000) 625-630
53. Welters M.J., de Jong A., van den Eeden S.J., van der Hulst J.M., Kwappenberg K.M., Hassane S., Franken K.L., Drijfhout J.W., Fleuren G.J., Kenter G., Melief C.J., Offringa R., and van der Burg S.H. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63 (2003) 636-641
54. Draenert R., Altfeld M., Brander C., Basgoz N., Corcoran C., Wurcel A.G., Stone D.R., Kalams S.A., Trocha A., Addo M.M., Goulder P.J., and Walker B.D. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 275 (2003) 19-29
55. de Jong, van Poelgeest M.I., van der Hulst J.M., Drijfhout J.W., Fleuren G.J., Melief C.J., Kenter G., Offringa R., and van der Burg S.H. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+T-cell immunity against early antigens E2 and E6. Cancer Res. 64 (2004) 5449-5455
56. de Jong, van der Hulst J.M., Kenter G.G., Drijfhout J.W., Franken K.L., Vermeij P., Offringa R., van der Burg S.H., and Melief C.J. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int. J. Cancer 114 (2005) 274-282
57. Raju R., Diethelm-Okita B., Okita D., and Conti-Fine B.M. Epitope repertoire of human CD4+ lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences. J. Autoimmun. 9 (1996) 79-88
58. Vambutas, Devoti J., Nouri M., Drijfhout J.W., Lipford G.B., Bonagura V.R., Burg S.H., and Melief C.J. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 23 (2005) 5271-5280
59. Berzofsky J.A., Pendleton C.D., Clerici M., Ahlers J., Lucey D.R., Putney S.D., and Shearer G.M. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88 (1991) 876-884
60. van der Burg S.H., Kwappenberg K.M., Geluk A., van der Kruk M., Pontesilli O., Hovenkamp E., Franken K.L., van Meijgaarden K.E., Drijfhout J.W., Ottenhoff T.H., Melief C.J., and Offringa R. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+T cells by at least four unrelated HLA-DR molecules. J. Immunol. 162 (1999) 152-160
61. Buseyne F., McChesney M., Porrot F., Kovarik S., Guy B., and Riviere Y. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J. Virol. 67 (1993) 694-702
62. Lamonaca V., Missale G., Urbani S., Pilli M., Boni C., Mori C., Sette A., Massari M., Southwood S., Bertoni R., Valli A., Fiaccadori F., and Ferrari C. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 30 (1999) 1088-1098
63. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., and Offringa R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 (2001) 3652-3660
64. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., and Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20 (2002) 2624-2632
65. Yu X.G., Addo M.M., Perkins B.A., Wej F., Rathod A., Geer S.C., Parta M., Cohen D., Stone D.R., Russell C.J., Tanzi G., Mei S., Wurcel A.G., Frahm N., Lichterfeld M., Heath L., Mullins J.I., Marincola F., Goulder P.J., Brander C., Allen T., Cao Y., Walker B.D., and Altfeld M. Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and caucasians. AIDS Res. Hum. Retrovir. 20 (2004) 557-564
66. Welters M.J., Filippov D.V., van den Eeden S.J., Franken K.L., Nouta J., Valentijn A.R., van der Marel G.A., Overkleeft H.S., Lipford G., Offringa R., Melief C.J., van Boom J.H., van der Burg S.H., and Drijfhout J.W. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine 23 (2004) 305-311
67. Weber J., Sondak V.K., Scotland R., Phillip R., Wang F., Rubio V., Stuge T.B., Groshen S.G., Gee C., Jeffery G.G., Sian S., and Lee P.P. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97 (2003) 186-200
68. *A0201 + melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8 (2002) 967-972
69. Melief C.J.M., Toes R.E.M., Medema J.P., Van der Burg S.H., Ossendorp F., and Offringa R. Strategies for immunotherapy of cancer. Adv. Immunol. 75 (2000) 235-281
70. Heath W.R., and Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19 (2001) 47-64
71. Melief C.J., Van Der Burg S.H., Toes R.E., Ossendorp F., and Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188 (2002) 177-182
72. van Driel W.J., Ressing M.E., Kenter G.G., Brandt R.M., Krul E.J., van Rossum A.B., Schuuring E., Offringa R., Bauknecht T., Tamm-Hermelink A., van Dam P.A., Fleuren G.J., Kast W.M., Melief C.J., and Trimbos J.B. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35 (1999) 946-952
73. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., and Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194 (2001) 863-869
74. Mazzoni, and Segal D.M. Controlling the Toll road to dendritic cell polarization. J. Leukoc. Biol. 75 (2004) 721-730
75. Ito T., Amakawa R., and Fukuhara S. Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. Hum. Immunol. 63 (2002) 1120-1125
76. Gerard C.M., Baudson N., Kraemer K., Bruck C., Garcon N., Paterson Y., Pan Z.K., and Pardoll D. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19 (2001) 2583-2589
77. Fujimoto, Nakagawa Y., Ohara K., and Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int. Immunol. 16 (2004) 55-63
78. Schwarz K., Storni T., Manolova V., Didierlaurent A., Sirard J.C., Rothlisberger P., and Bachmann M.F. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33 (2003) 1465-1470
79. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., Vasilakos J.P., Noelle R.J., and Kedl R.M. Combined TLR and CD40 triggering induces potent CD8+T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199 (2004) 775-784
80. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., and Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+T cell responses. J. Immunol. 174 (2005) 7676-7683
81. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174 (2005) 2476-2480
82. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., and Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5 (1999) 774-779
83. den Boer A.T., Diehl L., van Mierlo G.J., van der Voort E.I., Fransen M.F., Krimpenfort P., Melief C.J., Offringa R., and Toes R.E. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 167 (2001) 2522-2528
84. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6 (2005) 769-776
85. Speiser D.E., Lienard D., Pittet M.J., Batard P., Rimoldi D., Guillaume P., Cerottini J.C., and Romero P. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 32 (2002) 731-741
86. Monsurro V., Wang E., Panelli M.C., Nagorsen D., Jin P., Katia Z., Smith K., Ngalame Y., Even J., and Marincola F.M. Active-specific immunization against melanoma: is the problem at the receiving end?. Semin. Cancer Biol. 13 (2003) 473-480
87. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., and Romero P. Rapid and strong human CD8+T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005) 739-746
88. Liu L., Xu Z., Fuhlbrigge R.C., Pena-Cruz V., Lieberman J., and Kupper T.S. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J. Virol. 79 (2005) 7363-7370
89. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., Richman D.D., Eiden Jr. J.J., Spiegelberg H.L., and Raz E. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30 (2000) 1939-1947
90. Shirota H., Sano K., Kikuchi T., Tamura G., and Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164 (2000) 5575-5582
91. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., Smith C., Zeng W., and Brown L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 15440-15445
92. Roth, Rohrbach F., Weth R., Frisch B., Schuber F., and Wels W.S. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 92 (2005) 1421-1429
93. Daftarian P., Sharan R., Haq W., Ali S., Longmate J., Termini J., and Diamond D.J. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23 (2005) 3453-3468
94. Rouvio O., Dvorkin T., Amir-Kroll H., Atias D., Cohen I.R., Rager-Zisman B., and Porgador A. Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland. Vaccine 23 (2005) 3508-3518
95. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
96. Naylor K., Li G., Vallejo A.N., Lee W.W., Koetz K., Bryl E., Witkowski J., Fulbright J., Weyand C.M., and Goronzy J.J. The influence of age on T cell generation and TCR diversity. J. Immunol. 174 (2005) 7446-7452
97. Baldwin P.J., Van Der Burg S.H., Boswell C.M., Offringa R., Hickling J.K., Dobson J., Roberts J.S., Latimer J.A., Moseley R.P., Coleman N., Stanley M.A., and Sterling J.C. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9 (2003) 5205-5213
98. Smyth L.J., Van Poelgeest M.I., Davidson E.J., Kwappenberg K.M., Burt D., Sehr P., Pawlita M., Man S., Hickling J.K., Fiander A.N., Tristram A., Kitchener H.C., Offringa R., Stern P.L., and Van Der Burg S.H. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10 (2004) 2954-2961
99. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., Royal R.E., Kammula U., Restifo N.P., Hughes M.S., Schwartzentruber D., Berman D.M., Schwarz S.L., Ngo L.T., Mavroukakis S.A., White D.E., and Steinberg S.M. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+T cells in patients with melanoma. J. Immunol. 175 (2005) 6169-6176
100. Marincola F.M., and Ferrone S. Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin. Cancer Biol. 13 (2003) 387-389
101. Marincola F.M., Wang E., Herlyn M., Seliger B., and Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24 (2003) 335-342
102. Fritsch M., Rosenberg S.A., and Duray P.H. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. J. Immunother. 23 (2000) 557-569
103. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Perez-Diez A., Petersen D., Zhao Y., Simon R., Powell J.I., Asaki E., Alexander H.R., Duray P.H., Herlyn M., Restifo N.P., Liu E.T., Rosenberg S.A., and Marincola F.M. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62 (2002) 3581-3586
104. Davidson E.J., Boswell C.M., Sehr P., Pawlita M., Tomlinson A.E., McVey R.J., Dobson J., Roberts J.S., Hickling J., Kitchener H.C., and Stern P.L. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63 (2003) 6032-6041
105. Murphy W.J., Welniak L., Back T., Hixon J., Subleski J., Seki N., Wigginton J.M., Wilson S.E., Blazar B.R., Malyguine A.M., Sayers T.J., and Wiltrout R.H. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J. Immunol. 170 (2003) 2727-2733
106. van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., Melief C.J., and Toes R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5561-5566
107. van Mierlo G.J., Boonman Z.F., Dumortier H.M., den Boer A.T., Fransen M.F., Nouta J., van der Voort E.I., Offringa R., Toes R.E., and Melief C.J. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173 (2004) 6753-6759
108. Daniels G.A., Sanchez-Perez L., Diaz R.M., Kottke T., Thompson J., Lai M., Gough M., Karim M., Bushell A., Chong H., Melcher A., Harrington K., and Vile R.G. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22 (2004) 1125-1132
109. van Poelgeest M.I.E., van Seters M., van Beurden M., Kwappenberg K.M., Heijmans-Antonissen C., Drijfhout J.W., Melief C.J.M., Kenter G.G., Helmerhorst T.J.M., Offringa R., and van der Burg S.H. Detection of HPV16-specific CD4+T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin. Cancer Res. 11 (2005) 5273-5280
110. Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., and Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. 149 Suppl 66 (2003) 53-56
111. Wenzel J., Uerlich M., Haller O., Bieber T., and Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J. Cutan. Pathol. 32 (2005) 257-262
112. van Seters M., Fons G., and van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J. Reprod. Med. 47 (2002) 701-705
113. Panelli M.C., Wang E., Phan G., Puhlmann M., Miller L., Ohnmacht G.A., Klein H.G., and Marincola F.M. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 3 (2002) (RESEARCH0035)
114. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Hibbitts S., Grosh W.W., Chianese-Bullock K.A., Bissonette E.A., Barnd D.L., Deacon D.H., Patterson J.W., Parekh J., Neese P.Y., Woodson E.M., Wiernasz C.J., and Merrill P. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22 (2004) 4474-4485
115. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Sznol M., Schwarz S.L., Spiess P.J., Wunderlich J.R., Seipp C.A., Einhorn J.H., Rogers-Freezer L., and White D.E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163 (1999) 1690-1695
116. Andersen M.H., Gehl J., Reker S., Geertsen P., Becker J.C., and thor Stratem P. Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil?. J. Clin. Oncol. 23 (2005) 5265-5267 (author reply 5267-5268)
117. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C., and Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65 (2005) 5009-5014